Tags

Type your tag names separated by a space and hit enter

[Apomorphine for treatment of "off-periods" in Parkinson's disease].
Harefuah. 1999 Nov 15; 137(10):444-6, 512, 511.H

Abstract

After 3-5 years of continuous use of 1-dopa preparations for Parkinson's disease, 25%-50% of patients develop side-effects such as the "on-off" phenomenon and involuntary movements that markedly impair function. One cause of these manifestations is evidently a disturbance in the absorption of 1-dopa. We attempted to avoid this problem by using subcutaneous injections. Apomorphine is a rapid-acting dopamine agonist which causes a return from "off" to "on" within minutes. We present the results of a trial of subcutaneous injections of apomorphine in 22 Parkinsonian patients (12 males, 10 females) with severe motor fluctuations. During 5 days prior to the apomorphine all received Motilium (domperidone, 60 mg/d) to prevent nausea and vomiting. All were hospitalized initially to determine optimal dosage and to teach them the technique of self-injection. 2 to 4 mg of apomorphine were injected 1 to 3 times daily for 2 to 12 months. In 17 patients (80%) "off" periods were reduced without significant side-effects. Apomorphine seems to be effective, tolerable treatment for shortening 1-dopa induced "off" periods.

Authors+Show Affiliations

Dept. of Neurology, Rabin Medical Center, Petah Tikva.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
English Abstract
Journal Article
Multicenter Study

Language

heb

PubMed ID

10959339

Citation

Zoldan, J, et al. "[Apomorphine for Treatment of "off-periods" in Parkinson's Disease]." Harefuah, vol. 137, no. 10, 1999, pp. 444-6, 512, 511.
Zoldan J, Merims D, Kuritzky A, et al. [Apomorphine for treatment of "off-periods" in Parkinson's disease]. Harefuah. 1999;137(10):444-6, 512, 511.
Zoldan, J., Merims, D., Kuritzky, A., Ziv, I., & Melamed, E. (1999). [Apomorphine for treatment of "off-periods" in Parkinson's disease]. Harefuah, 137(10), 444-6, 512, 511.
Zoldan J, et al. [Apomorphine for Treatment of "off-periods" in Parkinson's Disease]. Harefuah. 1999 Nov 15;137(10):444-6, 512, 511. PubMed PMID: 10959339.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - [Apomorphine for treatment of "off-periods" in Parkinson's disease]. AU - Zoldan,J, AU - Merims,D, AU - Kuritzky,A, AU - Ziv,I, AU - Melamed,E, PY - 2000/8/26/pubmed PY - 2000/9/30/medline PY - 2000/8/26/entrez SP - 444-6, 512, 511 JF - Harefuah JO - Harefuah VL - 137 IS - 10 N2 - After 3-5 years of continuous use of 1-dopa preparations for Parkinson's disease, 25%-50% of patients develop side-effects such as the "on-off" phenomenon and involuntary movements that markedly impair function. One cause of these manifestations is evidently a disturbance in the absorption of 1-dopa. We attempted to avoid this problem by using subcutaneous injections. Apomorphine is a rapid-acting dopamine agonist which causes a return from "off" to "on" within minutes. We present the results of a trial of subcutaneous injections of apomorphine in 22 Parkinsonian patients (12 males, 10 females) with severe motor fluctuations. During 5 days prior to the apomorphine all received Motilium (domperidone, 60 mg/d) to prevent nausea and vomiting. All were hospitalized initially to determine optimal dosage and to teach them the technique of self-injection. 2 to 4 mg of apomorphine were injected 1 to 3 times daily for 2 to 12 months. In 17 patients (80%) "off" periods were reduced without significant side-effects. Apomorphine seems to be effective, tolerable treatment for shortening 1-dopa induced "off" periods. SN - 0017-7768 UR - https://www.unboundmedicine.com/medline/citation/10959339/[Apomorphine_for_treatment_of_"off_periods"_in_Parkinson's_disease]_ L2 - https://medlineplus.gov/parkinsonsdisease.html DB - PRIME DP - Unbound Medicine ER -